Effect Of Adjuvant HAIC On Survival Of Patients With Primary Hepatocellular Carcinoma After Hepatectomy

Objective: To explore the efficacy and safety of combined hepatectomy and adjuvant HAIC in the treatment of resectable hepatocellular carcinoma.To provide reference for delaying postoperative recurrence in patients with liver cancer.Methods: From January 2017 to January 2022,39 HCC patients(experimental group)received adjuvant HAIC after hepatectomy,and 78 HCC patients(control group)only received hepatectomy.Preoperative age,gender,BMI and other basic information of patients;Blood index;Basic liver disease;Imaging condition;Pathological findings of the excised specimen;HAIC treatment duration and safety data were collected.Diseasefree survival and overall survival were compared between the two groups,and subgroup analysis was conducted to evaluate the survival benefits of different subgroups.Finally,the risk factors that significantly affected DFS and OS in HCC patients were obtained through single factor analysis.Results: The median disease-free survival in the experimental group was significantly higher than that in the control group(33 months vs.16 months,P=0.021),and no patients in the experimental group had catheter-related complications or intolerable adverse reactions.In addition,adjuvant HIAC therapy was associated with a lower risk ratio(HR)for recurrence(P=0.005)and death(P=0.004)in HCC patients.Stage C of BCLC and tumor diameter > 7cm were independent risk factors for survival of patients with HCC(P < 0.001 and P=0.02).Conclusions: Adjuvant HAIC after hepatectomy can reduce the risk of recurrence/death in patients with hepatocellular carcinoma,and adjuvant HAIC therapy should be actively used in patients with high-risk recurrence factors.